Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 19/20 | 1.00 |
| ▸ | HTR2A | P28223 | 18/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-243213 SCHEMBL31060820 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL677610 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL18321797 | 0.99 | HTR2C (0.98) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL7473195 | 0.99 | HTR2C (0.98) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL7078894 | 0.93 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL7082914 | 0.90 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL7473325 | 0.88 | HTR2A (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL2229787 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-242084 SCHEMBL29388888 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-242084 SCHEMBL29462298 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | TERRAN BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| US-20250129064-A1 | PRODRUGS OF 2-BROMO-LSD (2-BROMOLYSERGIC ACID DIETHYLAMIDE) | TERRAN BIOSCIENCES INC. | 2025-04-24 | — | — | US | claimed |
| US-20250129054-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY-N-METHCATHINONE AND USES THEREOF | TERRAN BIOSCIENCES INC (US) | 2025-04-24 | — | — | US | claimed |
| US-20250109130-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 2-BROMO-LSD, LSD, ALD-52, AND 1P-LSD | TERRAN BIOSCIENCES INC (US) | 2025-04-03 | — | — | US | claimed |
| US-20250091993-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | TERRAN BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | claimed |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2025-02-27 | — | — | US | claimed |
| US-20250034105-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2025-01-30 | — | — | US | claimed |
| US-20250011351-A1 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | TERRAN BIOSCIENCES INC (US) | 2025-01-09 | — | — | US | claimed |
| EP-4448518-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 2-BROMO-LSD, LSD, ALD-52, AND 1P-LSD | Terran Biosciences Inc. (US) | 2024-10-23 | — | — | EP | claimed |
| WO-2023092044-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| WO-2023086962-A1 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-05-19 | — | — | WO | claimed |
| WO-2023087034-A1 | SALTS AND SOLID FORMS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| WO-2023081899-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2023081897-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2023081895-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (MDAI) | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2023077125-A2 | AZEPINO-INDOLES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| CN-114599355-A | Method for treating psychological and cerebral diseases | 马里兰大学巴尔的摩分校 | 2022-06-07 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129054-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY-N-METHCATHINONE AND USES THEREOF | CYP2C19, CYP11B1, CYP2D6 | HTR2C 433/4885HTR2B 489/4885HTR2A 973/4885 |
| US-20250091993-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | SLC1A2, SLC6A4, SLC6A3 | HTR2C 44/4885HTR2B 397/4885HTR2A 48/4885 |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | DRD2, HTR1D, DRD1 | HTR2C 4/4885HTR2B 33/4885HTR2A 7/4885 |
| US-20250109130-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 2-BROMO-LSD, LSD, ALD-52, AND 1P-LSD | LMNB2, CLN6, EPM2A | HTR2C 32/4885HTR2B 36/4885HTR2A 10/4885 |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | HTR2C 6/4885HTR2B 8/4885HTR2A 2/4885 |
| US-20250011351-A1 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | AANAT, PSAP, SPTSSB | HTR2C 604/4885HTR2B 209/4885HTR2A 493/4885 |
| US-20250034105-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | DBH, PNMT, MBTD1 | HTR2C 208/4885HTR2B 43/4885HTR2A 341/4885 |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | SLC6A4, SLC6A3, SLC6A2 | HTR2C 60/4885HTR2B 168/4885HTR2A 91/4885 |
| US-20250129064-A1 | PRODRUGS OF 2-BROMO-LSD (2-BROMOLYSERGIC ACID DIETHYLAMIDE) | GBA2, GBA1, SLC18A2 | HTR2C 16/4885HTR2B 23/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.